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Dysfunctions of the F1Fo-ATPase complex cause severe mitochondrial diseases affecting primarily the paediatric population. While in the
maternally inherited ATPase defects due to mtDNA mutations in the ATP6 gene the enzyme is structurally and functionally modified, in
ATPase defects of nuclear origin mitochondria contain a decreased amount of otherwise normal enzyme. In this case biosynthesis of ATPase
is down-regulated due to a block at the early stage of enzyme assembly—formation of the F1 catalytic part. The pathogenetic mechanism
implicates dysfunction of Atp12 or other F1-specific assembly factors. For cellular energetics, however, the negative consequences may be
quite similar irrespective of whether the ATPase dysfunction is of mitochondrial or nuclear origin.
D 2004 Elsevier B.V. All rights reserved.Keywords: Mitochondrial disease; Cardiomyopathy; ATP synthase; Oxidative phosphorylation; Respiratory chain complex1. Introduction
Last decade of bioenergetic research on mitochondrial
diseases has uncovered an increasing number of human
mitochondrial disorders that are caused by mutations in
nuclear genes encoding the subunits of oxidative phospho-
rylation complexes (OXPHOS), or other proteins that are
essential either for the biosynthesis of specific cofactors
(such as heme) or assembly of heterooligomeric OXPHOS
complexes from individual subunits (for review, see Ref.
[1]). Up to now, numerous mutations in nuclear genes have
been shown to cause a dysfunction of all mitochondrial
respiratory chain complexes, NADH dehydrogenase (Com-
plex I), succinate dehydrogenase (Complex II), bc1 complex
(Complex III), cytochrome c oxidase (Complex IV) and also
F1Fo-ATP synthase (ATPase, Complex V). Very often, these
defects manifest rather early and affect paediatric popula-
tion. Interestingly, the Complex I defects are mostly
connected with mutations in genes encoding the subunits0005-2728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2004.04.012
Abbreviations: OXPHOS, oxidative phosphorylation; ATPase, mito-
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E-mail address: houstek@biomed.cas.cz (J. Housˇteˇk).of the complex, while Complex IV and Complex III defects
are caused by mutations in specific assembly proteins or
biosynthetic factors. To the same category apparently be-
long the ATPase deficiencies of nuclear origin that are rather
rare and biochemically manifest as a reduction of cellular
content of ATPase complex that is otherwise structurally
and functionally normal.2. Selective defects of mitochondrial ATPase
Mitochondrial ATPase is the key enzyme of cellular
energy conversion. ATPase uses the H+ gradient generated
by the respiratory chain as a driving force for the synthesis
of ATP from ADP and phosphate. The mammalian ATPase
complex is formed by 16 different subunits [2] and consists
of the globular F1 catalytic part connected by two stalks to
the membrane-embedded Fo moiety, which translocates
protons across the inner mitochondrial membrane. Two
Fo subunits, subunit a (ATP6) and A6L (ATP8), are coded
for by mitochondrial DNA (mtDNA) [3]; all other subunits
are nuclearly encoded. Mitochondrial encephalomyopathies
due to selective defects in mitochondrial ATPase are less
frequent than the disorders of the respiratory chain com-
plexes. They are mostly very severe and can be caused by
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genes.Table 1
Patients with mitochondrial ATPase deficiency
Case ATPase
(%)
Onset/
survival
Biochemical data
and phenotype
Reference
I < 10 neonate/15 months LA, methylglutaconic
aciduria, CM,
developmental delay
[26]
IIa < 30 neonate/2 days fatal LA, CM,
hepatomegaly
[27]
IIb < 30 neonate/2 days fatal LA, CM
IIIa < 20 neonate/32 days LA, CM, respiratory
failure
[22]
IIIb < 30 neonate/3 years LA, CM, short statute,
failure to thrive,
developmental delay
IV < 30 neonate/8 years LA, methylglutaconic
aciduria, CM,
developmental delay
[22]
V < 10 neonate/3 years LA, CM, developmental
delay
[28]
VI < 20 neonate/14 months LA, methylglutaconic
aciduria, dysmorphism,
enlarged liver,
marked brain atrophy
[29]
VII < 30 neonate/3 days fatal LA, enlarged liver,
small left ventricle,
intracranial haemorrhage
[29]
LA—lactic acidosis, CM—cardiomyopathy.3. ATP6 mutations
All maternally inherited primary ATPase defects are
associated with subunit a (see Ref. [4]), an essential com-
ponent, together with multiple copies of the subunit c of the
ATPase proton channel [5,6]. The ATP6 gene is a hotspot of
pathogenic mtDNA mutations affecting ATPase; no muta-
tions have been found in the ATP8 gene. ATP6 mutations
are mostly missense heteroplasmic mtDNA mutations af-
fecting the protonophoric function of the subunit a. Higher
prevalence show T8993G(C) mutations [7,8] which change
Leu156 to Arg or Pro. At a lower mutation load they are
manifested as a NARP syndrome (Neurogenic muscle
weakness, Ataxia, Retinitis Pigmentosa), at heteroplasmy
exceeding 90% they present as maternally inherited Leigh
syndrome (severe and fatal encephalopathy). Less frequent
are T9176G(C) mutations which change Leu217 [9,10] or a
T8851G mutation [11] affecting Trp109, both manifesting
also as striatal necrosis syndromes (see Ref. [4]). Impair-
ment of the ATPase H+ channel by different ATP6 mutations
results often, but not always, in decreased ATP production,
while the ATPase hydrolytic activity remains unchanged
[12,13]. Mitochondria from T8993G cells are capable of
ATP-dependent proton translocation [14] indicating that at
least the vectorial proton transport by the enzyme from
matrix to cytosol is unaffected. Increased lability of the
ATPase complex, possibly due to altered assembly of
subunit a, apparent as accumulation of incomplete ATPase
assemblies, has been described in T8993G mutation [13,15].
Interestingly, these assembly intermediates could not be
found in some other cases [16], which indicates that,
similarly as in segregation of ATP6 mutations [17], a
different nuclear background and participation of putative
regulatory factor(s) may be involved in their pathogenetic
mechanism.
A completely different type of pathogenic mechanism is
represented by homoplasmic mtDNA 2-bp microdeletion
9205delTA, so far found in two cases only [18,19]. This
mutation removes the stop codon of the ATP6 gene and
affects the cleavage site between ATP6 and COXIII tran-
scripts. The biochemical and clinical presentations of these
two cases are, however, strikingly different [20–22]. An
involvement of some nuclear-encoded factor operating at
the level of mitochondrial RNA processing is to be
expected. Several proteins have been described in yeast
(NCA2, NCA3, NAM1/MTF2, Aep3p) that are essential for
proper processing of mitochondrial RNAs, namely of the
ATP8–ATP6 cotranscript (see Ref. [23]), but their mamma-
lian orthologues were not found, possibly reflecting differ-
ences in the structure of mammalian mitochondrial RNAs
that, in comparison with yeast, lack introns and 3- and 5-
prime untranslated regions. Another group of factors in-volved in translation of mitochondrial RNAs is represented
by proteins mediating mRNA–ribosome interactions.
Search for mammalian orthologues in this group was more
successful and an LRPPRC protein was identified using
functional genomics approach [24]. It was shown that
mutation in the LRPPRC gene causes the Leigh syndrome
of French–Canadian type, which is a human mitochondrial
COX deficiency [25]. Identification of additional mamma-
lian factors specific for other mitochondrial transcripts can
be foreseen.4. ATPase defects of nuclear origin
ATPase defects due to a nuclear genome mutations where
an alteration of mtDNA genes was excluded are character-
ised as selective decrease of ATPase content that is caused
by diminished biosynthesis of the ATPase complex. An
increasing number of cases diagnosed recently (Table 1)
indicates that these defects may be more frequent than
originally expected. ATPase deficiency of possible non-
mitochondrial origin was first described in a child with 3-
methylglutaconic aciduria and severe lactic acidosis [26].
An extremely low ATPase activity and low, tightly coupled,
respiration rates were observed in muscle mitochondria, but
no mutation was found in mtDNA genes encoding ATPase
subunits. The nuclear origin of ATP synthase deficiency was
demonstrated for the first time in 1999 [27] in a new type of
fatal mitochondrial disorder. A child with severe lactic
acidosis, cardiomyopathy and hepatomegaly died 2 days
Fig. 1. OXPHOS complexes in a patient with ATPase deficiency. Blue-Native/SDS two-dimensional electrophoresis was performed using laurylmaltoside-
solubilised proteins from heart mitochondria from patient (IIa in Table 1) and control, the gel was stained with Coomassie blue. The position of ATPase
complex and of respiratory chain complexes I, III and IV is indicated; white arrows point to a/h F1-ATPase subunits.
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activity and ATP production was associated with cor-
responding selective decrease of the content of the ATPase
complex, which had normal size and subunit composition
(Fig. 1). Transmitochondrial cybrid cells made of patient’s
fibroblasts fully complemented the ATPase defect and
confirmed the nuclear origin of impaired biogenesis of the
enzyme complex [27]. Later on, two other similar cases of
selective ATPase deficiency were found in the Czech
Republic [22] and one in Austria [28]. Most recently, two
patients with selective ATPase deficiency were described in
Belgium [29]. In one of them, De Meirleir et al. located the
pathogenic mutation in the ATP12 gene for the first time
(see further). As summarised in Table 1, most of the cases
showed a reduction of ATPase content to < 30% of the
control, early onset of the disease, cardiomyopathy and
survival of several days or weeks. Interestingly, methylglu-
taconic aciduria was found in several longer surviving
patients. One of them showed a different phenotype of
degenerative encephalopathy characterised by cortical and
subcortical atrophy [29].Fig. 2. ATPase assembly scheme.5. Altered biosynthesis of ATPase
The mechanism of ATPase biosynthesis is still not very
well understood. The mammalian enzyme is expected to
assemble stepwise (Fig. 2). Several transient assembly
intermediates have been identified with initial formation of
the F1 catalytic part to which the nuclear encoded membrane
sector subunits are added, followed by mtDNA-encoded
subunits [30–32]. Native forms of ATPase can be easily
revealed by Blue-Native electrophoresis [33] that became a
very powerful approach to diagnostics of mitochondrial
OXPHOS defects today. We have performed detailed stud-ies on most of the diagnosed cases of selective ATPase
deficiency and always found only a full-size ATPase com-
plex to be present in cells and isolated mitochondria from
the patient’s tissues [27]. No accumulation of assembly
intermediates analogous to subcomplexes observed in
ATP6 mutations or cells with doxycycline-inhibited transla-
tion of mitochondrial proteins [13,15,32] could be detected
in fibroblasts with ATPase defects of nuclear origin. In
[35S]-methionine labelling experiments, decreased biosyn-
thesis of the assembled ATPase has been found (Fig. 3). It
contrasted with the increased biosynthesis of the h subunit
of the F1 catalytic part that had a very short half-life [27].
The cells also showed extramitochondrial accumulation of
the h subunit, supporting the view that the biogenesis of
ATPase is disturbed at an early stage when the F1 catalytic
part is formed.6. F1-ATPase assembly and affected nuclear factor(s)
The possible cause of insufficient ATPase biosynthesis
can be a limited production or mutation of some of the
Fig. 3. Metabolic labelling of ATPase-deficient fibroblasts and derived transmitochondrial cybrids. Cells from patient (D) and control (5) were labelled for 3
h with [35S]methionine, followed by 3–48-h chase with excess cold methionine. Aliquots of solubilised OXPHOS complexes were analysed by two-
dimensional electrophoresis and radioactivity was determined by phosphorimaging (patient IIa in Table 1).
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mammalian tissues and it may vary also during ontogenetic
development. Physiologically ATPase is down-regulated
about 10-fold, relative to other OXPHOS complexes, in
thermogenic brown fat where the electrochemical potential
of proton gradient is dissipated in the form of heat by the
uncoupling protein UCP1 [34]. Interestingly, the two-di-
mensional electrophoretic pattern of OXPHOS proteins in
brown fat is almost identical with that found in patients with
ATPase deficiency. In brown fat a selective transcriptional
down-regulation of subunit c isogenes P1 and P2 and
availability of the subunit c has been found as a limiting
step for de novo synthesis of ATPase [35]. The transcrip-
tional control of subunit c genes has been implicated in
control of the cellular content of ATPase also in other
mammalian tissues [36,37]. However, in ATPase-deficient
patients expression of subunit c isogenes was normal or
even increased [27] and the mRNA levels for other ATPase
subunits did not show a significant decrease. As also
sequencing of cDNAs of F1 and Fo subunits from patient
cells was unable to detect any pathogenic mutation, the
possible cause of the disease might be associated with a
dysfunction of an ATPase-specific assembly factor.
Biosynthesis of eukaryotic ATPase is a highly ordered
process, which involves several ATPase-specific assembly
proteins. Studies in yeast identified five chaperone-type
factors necessary for the assembly of the functional en-
zyme. Atp10p and Atp22p were found to mediate Fo
assembly [38,39] while Atp11p, Atp12p and Fmc1p are
required for the F1 part [40,41]. Fmc1p is essential at
elevated growth temperatures but FMC1 deletion could be
rescued by overexpression of Atp12p [41]. Recently, hu-
man orthologues of Atp11p and Atp12p (Atpaf1p and
Atpaf2p according to new nomenclature) have also been
identified. Like the yeast proteins, human Atp11p has
chaperone-like activity toward the h subunit and human
Atp12p interacts with the a subunit [42,43]. Expression of
ATP11 and ATP12 in mammalian tissues is about two
orders of magnitude lower than expression of genes for
the corresponding F1 subunits, in accordance with the
chaperone function of these proteins. Interestingly, ATP11
expression in mouse is nearly constant in all tissues,
indicating that ATP11 rather behaves like a maintenancegene. In contrast, ATP12 expression differed up to 30-fold
in diferent tissues and it was found to correlate well with
mRNA levels of both F1-a and F1-h (BATHkidney, liver>-
heart, brain>skeletal muscle), showing the highest mRNA
level in the thermogenic, ATPase-poor brown adipose tissue
[44].
The most recent molecular genetic studies by De Meirleir
et al. [29] in two patients from Belgium with ATPase
deficiency identified in one case the first mutation in
ATP12 (patient 6 in Table 1), which was homozygous
TGG-AGG missense mutation in exon 3 changing Trp94 to
Arg. No mutation in ATP11 and ATP12 was present in the
second case. Similarly, we were unable to find any mutation
in other cases that have been analysed (patients II–V in Table
1). Moreover, we were also unable to detect any decrease in
ATP11 and ATP12 transcripts in these patients that would
indicate their decreased content. Taken together, the available
data suggest an involvement of another, yet unidentified
ATPase assembly factor. This view might also be supported
by the fact that the phenotype of the patient with ATP12
mutation—marked brain atrophy, significantly differs from
other patients presenting with cardiomyopathy (Table 1).7. Biochemical changes in nuclear ATPase defects
Pronounced reduction of ATPase content in patient’s
fibroblasts strongly decreased the synthesis of ATP, ADP-
stimulated respiration, and the discharge of mitochondrial
membrane potential which showed even higher steady state
values than the control cells [22,27,28]. However, even in
cells with 90% decrease of ATPase content, a significant
ATP production could be seen [28]. As apparent from
inhibitor titration studies [45,46], individual OXPHOS
enzymes of mitochondrial energy metabolism can be
inhibited to a certain extent without noticeable reduction
of the mitochondrial coupled respiration rate. These thres-
hold effects are different for individual OXPHOS com-
plexes and they also display tissue specificity. In the case
of ATPase, some 10% of normal activity of the enzyme was
found to be sufficient for 30–60% functionality of the
whole respiratory chain, depending on the type of tissue.
This would mean that, with respect of mitochondrial energy
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tolerated, at least under conditions when the energetic
demands of the patient’s organism are rather low.
For the pathogenetic mechanism of ATPase deficiency
thus may be more relevant the mitochondrial ROS produc-
tion related to the higher levels of DWm, observed inFig. 4. ROS production analysed by confocal microscopy in ATPase-deficient ce
H2DCFDA (5-(and-6)-chloromethyl-2V,7V-dichlorodihydrofluorescein diacetate)
microscope. (A) Increase in green fluorescence serves as a measure of ROS pro
fluorescent CM-DCFDA (fluorescein derivative). (B) Quantification of confocal
control cells, CM-DCFDA fluorescence was related to Mitotracker fluorescence.patient’s fibroblasts. An exponential increase of mitochon-
drial ROS production occurs at high levels of DWm above
140 mV [47,48]. On the contrary, decrease of DWm via
stimulation of ATP synthase activity, a low ATP/ADP ratio,
and substrate limitation or increased proton permeability
due to external or internal uncoupling lower the amount oflls. Intact fibroblasts (patient IV in Table 1) were labelled with 1 AM CM-
and 50 nM Mitotracker DeepRed and analysed on a Leica TCS SP2
duction in cell, as non-fluorescent CM-H2DCFDA is oxidized by ROS to
images is shown. To compensate for mitochondrial content in patient and
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intact fibroblasts from patients with ATPase deficiency
revealed pronounced activation of ROS production that
was prevented by an uncoupler (Fig. 4). Interestingly, cells
with ATP6 mutations also show an altered discharge of
DWm [22,50]. Therefore, it appears that the mitochondrial
membrane potential is generally increased in both types of
ATPase defects, irrespective of whether the inner mitochon-
drial membrane contains decreased amounts of normal
ATPase complexes or normal content of altered ATPase
complexes that are unable to operate as ATP synthase. In
both situations, therefore, up-regulation of ROS production
is to be expected to play a key role in the pathogenesis of the
disease.8. Conclusions
Involvement of nuclear genes in the pathogenesis of
primary ATPase defects resulting in severe mitochondrial
encephalo-cardiomyopathies may be rather complex. While
selective ATPase deficiency is caused by a dysfunction of
F1-specific, nuclear-encoded assembly factor(s), other nu-
clear genes are likely to be involved in transmission and
manifestation of mtDNA mutations in the ATP6 gene that
impair the function of the ATPase proton channel.Acknowledgements
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